Insight
Talha Badar: Outcome after stopping venetoclax and azacitidine
Photo taken from www.aacr.org

Talha Badar: Outcome after stopping venetoclax and azacitidine

Talha Badar shared on X:

“American Journal of Hematology, Blood Research Journal, Wiley Online Library.

Outcome after stopping venetoclax and azacitidine.

28/62 ND AML patients stopped hypomethylating agent and venetoclax.

With a median follow-up of 23 months (IQR, 20–32), mOS and treatment-free survival were 44 (IQR, 16-NR) and 16 (IQR, 8–27) months, respectively MRD -ve had 2 yrs treatment free survival of 80%.

RR cohort (n = 22), mOS and treatment-free survival were 19 (IQR, 17–31) and 10 (IQR, 5-NR) months, respectively. No different in outcome between patients who only stopped venetoclax vs. venetoclax-azacitidine.”

Talha Badar

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Authors: Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, David A. Sallman, Justine Decroocq, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Chantal Himberlin, Pierre Peterlin, Sarah Bonnet, Onyee Chan, Jeffrey Lancet, Rami Komrokji, François Vergez, Nicolas Chapuis, Tatiana Raskovalova, Adriana Plesa, Anne-Catherine Lhoumeau, Ariane Mineur, Marie Anne Hospital, Arnaud Pigneux, Norbert Vey, and Christian Récher.

 

Elen Baloyan

Author

Elen Baloyan

MD, Medical Oncologist, Vice President of News and Content strategy, OncoDaily, P53, Director of BIGR, Editor-in-Chief of OncoDaily Magazine

Elen Baloyan is a medical oncologist, Managing Editor of OncoDaily, and Editor-in-Chief of OncoDaily Magazine. She is a clinical research physician at the Immune Oncology Research Institute, with interests in immunotherapy, lung cancer, and global oncology. She is also a research fellow at the BG Lab, serves as Vice President of News and Content Strategy at P53 Inc., and oversees Hemostasis Today and Fertility News.
Adriana Plesa Alberto Santagostino American Journal of Hematology Amine Belhabri AML Anne-Catherine Lhoumeau Ariane Mineur Arnaud Pigneux azacitidine Blood Research Journal cancer Celestine Simand Chantal Himberlin Christian Récher Corentin Orvain David A. Sallman François Vergez Gaspar Aspas Requena hypomethylating agent Jeffrey Lancet Justine Decroocq Kamel Laribi Marie Anne Hospital Martin Carré Nicolas Chapuis Norbert Vey OncoDaily Oncology Onyee Chan Pierre Peterlin Pierre-Yves Dumas Rami Komrokji Sarah Bertoli Sarah Bonnet Sylvain Garciaz Talha Badar Tatiana Raskovalova venetoclax Wiley Online Library